Omicron News and Research

RSS

Prior COVID highly protective against severe disease ten months post-infection

In a recent study published in the Lancet, researchers performed a systematic review of scientific literature published from inception up to September 31, 2022, that documented the reduction in risk of coronavirus disease 2019 (COVID-19) among individuals with a prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vis-à-vis those with no COVID-19 history.

19 Feb 2023

After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2

In a recent study published in the journal Eurosurveillance, researchers investigated whether prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) vaccination protected against SARS-CoV-2 Omicron variant of concern (VOC) BA.4/5 sub-VOC or BA.2 sub-VOC infections.

19 Feb 2023

How effective has the bivalent booster COVID vaccination been?

In a recent study published in the journal Eurosurveillance, researchers estimated the effectiveness of bivalent messenger ribonucleic acid (mRNA) vaccines targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 subvariant and the original Wuhan-Hu1 strain against Omicron infections in the vaccinated population of the Netherlands between 26 September and 19 December 2022.

19 Feb 2023

Epidemic dynamics of the SARS-CoV-2 Omicron variant in China during the transition from 'zero-COVID' to little-to-no intervention efforts

Researchers quantified the magnitude and rate of the SARS-CoV-2 Omicron variant outbreak in China following the abrupt exit from the ‘zero-COVID’ guidelines.

17 Feb 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

The relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine series

Researchers evaluated whether serologic testing could help estimate the risk of SARS-CoV-2 infection in vaccinated individuals who had not received a booster dose.

17 Feb 2023

Omicron has higher risk of in-hospital mortality compared to influenza

In a recent study published in the journal JAMA Network Open, researchers compared the hospital outcomes of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant with those of influenza patients in Switzerland, assess the current disease burden due to coronavirus disease 2019 (COVID-19).

16 Feb 2023

Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomes

Researchers evaluated the effectiveness of nirmatrelvir–ritonavir in preventing coronavirus disease 2019 (COVID-19) severity outcomes during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant predominance.

16 Feb 2023

Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antivirals

Researchers performed a retrospective population-wide cohort study using anonymized data in Hong Kong, China, between February 26 and July 3, 2022.

16 Feb 2023

COVID-19 is associated with higher diabetes and hypertension risk

In a recent study published in the journal JAMA Network Open, researchers determined new-onset diabetes, hypertension, and hyperlipidemia, all cardiometabolic disorders in adult coronavirus disease 2019 (COVID-19) patients under treatment in California, United States of America (USA) between March 2020 and June 2022.

15 Feb 2023

Nirmatrelvir-ritonavir therapy effective against Omicron BA.4/BA.5

Researchers examine non-hospitalized adult patients with COVID-19 treated with nirmatrelvir-ritonavir.

15 Feb 2023

New insights into the driving factors of COVID-19 dynamics in England

In a recent study posted to the medRxiv* preprint server, researchers provided quantitative estimates of population-level drivers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and infection severity by fitting coronavirus disease 2019 (COVID-19) epidemiological surveillance data from England into dynamic transmission models.

15 Feb 2023

Bivalent and monovalent mRNA boosters induce similar antibody response against Omicron subvariants

A study conducted by US-based scientists claims that bivalent mRNA booster vaccines do not have any added benefits over monovalent booster vaccines in terms of inducing robust and durable neutralizing antibody response against omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Feb 2023

NIH initiates a clinical trial evaluating an investigational antiviral for treatment of COVID-19

Bivalent booster recipients show slightly higher protection against infection and significantly higher protection against death than monovalent booster recipients

Researchers reported the immune protection conferred by monovalent COVID-19 vaccines and bivalent booster doses.

13 Feb 2023

Omicron News and Research

Prior COVID highly protective against severe disease ten months post-infection

After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2

How effective has the bivalent booster COVID vaccination been?

Epidemic dynamics of the SARS-CoV-2 Omicron variant in China during the transition from 'zero-COVID' to little-to-no intervention efforts

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

The relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine series

Omicron has higher risk of in-hospital mortality compared to influenza

Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomes

Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antivirals

COVID-19 is associated with higher diabetes and hypertension risk

Nirmatrelvir-ritonavir therapy effective against Omicron BA.4/BA.5

New insights into the driving factors of COVID-19 dynamics in England

Bivalent and monovalent mRNA boosters induce similar antibody response against Omicron subvariants

NIH initiates a clinical trial evaluating an investigational antiviral for treatment of COVID-19

Meta-analysis showcases the long-term benefits of COVID-19 vaccines against hospitalization & death

Changes in SARS-CoV-2 antibody titers after COVID-19 vaccination

Omicron variant of SARS-CoV-2 is less infectious in dogs and cats

Omicron BQ and XBB subvariants most resistant viruses to monoclonal antibodies

Paxlovid can prevent hospitalization and death for patients infected with Omicron variants, study shows

Bivalent booster recipients show slightly higher protection against infection and significantly higher protection against death than monovalent booster recipients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News